Amylyx Pharmaceuticals (AMLX) EBT Margin: 2021-2024
Historic EBT Margin for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -145.57%.
- Amylyx Pharmaceuticals' EBT Margin fell 15068.00% to -145.57% in Q4 2024 from the same period last year, while for Dec 2024 it was -259.77%, marking a year-over-year decrease of 27235.00%. This contributed to the annual value of -264.42% for FY2024, which is 27700.00% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its EBT Margin stood at -145.57% for Q4 2024, which was up 99.17% from -17,476.92% recorded in Q3 2024.
- Amylyx Pharmaceuticals' EBT Margin's 5-year high stood at 22.15% during Q2 2023, with a 5-year trough of -17,476.92% in Q3 2024.
- Moreover, its 3-year median value for EBT Margin was -139.65% (2024), whereas its average is -3,482.69%.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' EBT Margin soared by 987,031bps in 2023, and later crashed by 1,749,696bps in 2024.
- Amylyx Pharmaceuticals' EBT Margin (Quarterly) stood at -8,120.00% in 2021, then slumped by 173,027bps to -162.77% in 2022, then surged by 16,789bps to 5.11% in 2023, then plummeted by 15,068bps to -145.57% in 2024.
- Its EBT Margin stands at -145.57% for Q4 2024, versus -17,476.92% for Q3 2024 and -7,106.55% for Q2 2024.